Clinical characteristics of study patients with multiple sclerosis (N=598).
| Variables | n | (%) |
|---|---|---|
| Gender | ||
| Male | 214 | (35.8) |
| Female | 384 | (64.2) |
| Marital status | ||
| Single | 250 | (41.8) |
| Married | 310 | (51.8) |
| Divorced | 36 | (6) |
| Widower | 2 | (0.4) |
| Education level | ||
| Illiterate | 4 | (0.7) |
| Primary | 12 | (2) |
| Intermediate | 28 | (4.7) |
| Secondary | 140 | (23.4) |
| University | 378 | (63.2) |
| Postgraduate | 36 | (6) |
| Regions | ||
| Southern | 170 | (28.4) |
| Middle | 150 | (25.1) |
| East | 114 | (19.1) |
| North | 28 | (4.7) |
| West | 136 | (22.7) |
| Age (years), mean±SD [range] | 32.4±8.4 | [15-60] |
| At disease onset, mean±SD [range] | 26.9±7.6 | [13-56] |
| Disease duration (years), mean±SD | 6.5±4.7 | |
| Number of admission, mean±SD | 1.4±1.7 | |
| Number of attacks during last 2 years), mean±SD [range] | 1.4±1.9 | [0-14] |
| Drug used now (n=558) | ||
| Interferon beta-1b (Betaferon) | 146 | (26.2) |
| Interferon beta-1a (Rebif) | 114 | (20.5) |
| Interferon beta-1a (Avonex) | 100 | (17.9) |
| Teriflunomide (Aubagio) | 20 | (3.6) |
| Dimethyl fumarate (Tecfidera) | 18 | (3.2) |
| Fingolimod (Gilenya) | 108 | (19.3) |
| Natalizumab (Tysabri) | 46 | (8.2) |
| Rituximab (Rituxan) | 4 | (0.7) |
| Alemtuzumab (Lemetrada) | 2 | (0.5) |